Abstract
In the 1970s, treatment with thyroid extract was superseded by levothyroxine, a synthetic l form of tetraiodothyronine. Since then, no major innovation has emerged for the treatment of hypothyroidism. The biochemical definition of subclinical hypothyroidism is a matter of debate. Indiscriminate screening for hypothyroidism has led to overdiagnosis and treatment initiation at lower serum levels of thyroid-stimulating hormone (TSH) than previously. Adverse health effects have been documented in individuals with hypothyroidism or hyperthyroidism, and these adverse effects can affect health-related quality of life (QOL). Levothyroxine substitution improves, but does not always normalize, QOL, especially for individuals with mild hypothyroidism. However, neither studies combining levothyroxine and liothyronine (the synthetic form of tri-iodothyronine) nor the use of desiccated thyroid extract have shown robust improvements in patient satisfaction. Future studies should focus not only on a better understanding of an individual’s TSH set point (the innate narrow physiological range of serum concentration of TSH in an individual, before the onset of hypothyroidism) and alternative thyroid hormone combinations and formulations, but also on autoimmunity and comorbidities unrelated to hypothyroidism as drivers of patient dissatisfaction. Attention to the long-term health consequences of hypothyroidism, beyond QOL, and the risks of overtreatment is imperative.
Key points
-
Epidemiological data suggest that the prevalence of (typically mild) hypothyroidism is increasing, partly owing to increased screening, which has led to a lower threshold for initiating treatment with levothyroxine.
-
Approximately 10–15% of individuals with hypothyroidism treated with levothyroxine experience persistent symptoms and dissatisfaction with therapy (that might or might not be due to their hypothyroidism), which can lead to overtreatment.
-
Health-related quality of life (QOL) is a complementary measure to morbidity and mortality; it should be measured with a validated thyroid-specific instrument for patient-related outcomes.
-
Poor QOL has been attributed to failure to achieve adequate T3 levels in tissues, polymorphisms in deiodinase and hormone transporter genes and/or symptoms unrelated to hypothyroidism such as autoimmune disease.
-
There is little evidence of durable QOL improvements with levothyroxine and liothyronine combination therapy, or from therapy with desiccated thyroid hormone, from a multitude of randomized controlled trials and meta-analyses.
-
Future research should investigate non-thyroidal causes of impaired QOL in patients with hypothyroidism as, at present, overtreatment for hypothyroidism constitutes a greater threat to health than undertreatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
McAninch, E. A. & Bianco, A. C. The history and future of treatment of hypothyroidism. Ann. Intern. Med. 164, 50–56 (2016).
Escobar-Morreale, H. F., Obregon, M. J., Escobar del Rey, F. & Morreale de Escobar, G. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J. Clin. Invest. 96, 2828–2838 (1995).
Chaker, L., Bianco, A. C., Jonklaas, J. & Peeters, R. P. Hypothyroidism. Lancet 390, 1550–1562 (2017).
Okosieme, O. et al. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clin. Endocrinol. 84, 799–808 (2016).
Perros, P. European thyroid association guidelines on l-T4 + l-T3 combination for hypothyroidism: a weary step in the right direction. Eur. Thyroid J. 1, 51–54 (2012).
Taylor, P. N. et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Int. Med. 174, 32–39 (2014).
Toloza, F. J. K. et al. Patient experiences and perceptions associated with the use of desiccated thyroid extract. Medicina 56, 161 (2020).
Mitchell, A. L., Hegedus, L., Zarkovic, M., Hickey, J. L. & Perros, P. Patient satisfaction and quality of life in hypothyroidism: an online survey by the British Thyroid Foundation. Clin. Endocrinol. 94, 513–520 (2021).
Negro, R. et al. Use of thyroid hormones in hypothyroid and euthyroid patients; the 2019 Italian Survey. Eur. Thyroid. J. 9, 25–31 (2020).
Jonklaas, J., Tefera, E. & Shara, N. Short-term time trends in prescribing therapy for hypothyroidism: results of a survey of American Thyroid Association members. Front. Endocrinol. 10, 31 (2019).
la Cour, J. L. et al. Risk of over- and under- treatment with levothyroxine in primary care in Copenhagen, Denmark. Eur. J. Endocrinol. 185, 673–679 (2021).
Lillevang-Johansen, M., Abrahamsen, B., Jorgensen, H. L., Brix, T. H. & Hegedus, L. Over- and under-treatment of hypothyroidism is associated with excess mortality: a register-based cohort study. Thyroid 28, 566–574 (2018).
Perros, P., Nirantharakumar, K. & Hegedus, L. Recent evidence sets therapeutic targets for levothyroxine-treated patients with primary hypothyroidism based on risk of death. Eur. J. Endocrinol. 184, C1–C3 (2021).
Thvilum, M. et al. Increased risk of dementia in hypothyroidism: a Danish nationwide register-based study. Clin. Endocrinol. 94, 1017–1024 (2021).
Folkestad, L., Brandt, F., Lillevang-Johansen, M., Heiberg Brix, T. & Hegedüs, L. Graves’ disease and toxic nodular goiter, aggravated by duration of hyperthyroidism, are associated with Alzheimer’s and vascular dementia: a registry-based long-term follow-up of two large cohorts. Thyroid 30, 672–680 (2020).
Bianco, A. C. et al. Paradigms of dynamic control of thyroid hormone signaling. Endocr. Rev. 40, 1000–1047 (2019).
Evered, D. C., Ormston, B. J., Smith, P. A., Hall, R. & Bird, T. Grades of hypothyroidism. Br. Med. J. 1, 657–662 (1973).
Zulewski, H., Muller, B., Exer, P., Miserez, A. R. & Staub, J. J. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J. Clin. Endocrinol. Metab. 82, 771–776 (1997).
Wiersinga, W. M. Guidance in subclinical hyperthyroidism and subclinical hypothyroidism: are we making progress? Eur. Thyroid. J. 4, 143–148 (2015).
Mendes, D., Alves, C., Silverio, N. & Batel Marques, F. Prevalence of undiagnosed hypothyroidism in Europe: a systematic review and meta-analysis. Eur. Thyroid. J. 8, 130–143 (2019).
Carle, A. et al. Hypothyroid symptoms and the likelihood of overt thyroid failure: a population-based case-control study. Eur. J. Endocrinol. 171, 593–602 (2014).
Hoermann, R., Larisch, R., Dietrich, J. W. & Midgley, J. E. Derivation of a multivariate reference range for pituitary thyrotropin and thyroid hormones: diagnostic efficiency compared with conventional single-reference method. Eur. J. Endocrinol. 174, 735–743 (2016).
Fitzgerald, S. P., Bean, N. G., Falhammar, H. & Tuke, J. Clinical parameters are more likely to be associated with thyroid hormone levels than with thyrotropin levels: a systematic review and meta-analysis. Thyroid 30, 1695–1709 (2020).
Surks, M. I. & Hollowell, J. G. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J. Clin. Endocrinol. Metab. 92, 4575–4582 (2007).
Vadiveloo, T., Donnan, P. T., Murphy, M. J. & Leese, G. P. Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and Research Study (TEARS). J. Clin. Endocrinol. Metab. 98, 1147–1153 (2013).
Bano, A. et al. Association of thyroid function with life expectancy with and without cardiovascular disease: the Rotterdam study. JAMA Int. Med. 177, 1650–1657 (2017).
Somwaru, L. L., Rariy, C. M., Arnold, A. M. & Cappola, A. R. The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. J. Clin. Endocrinol. Metab. 97, 1962–1969 (2012).
de Moura Souza, A. & Sichieri, R. Association between serum TSH concentration within the normal range and adiposity. Eur. J. Endocrinol. 165, 11–15 (2011).
Garber, J. R. et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22, 1200–1235 (2012).
Russell, W. et al. Free triiodothyronine has a distinct circadian rhythm that is delayed but parallels thyrotropin levels. J. Clin. Endocrinol. Metab. 93, 2300–2306 (2008).
Gereben, B. et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr. Rev. 29, 898–938 (2008).
Galton, V. A., Martinez, M. E., Dragon, J. A., St Germain, D. L. & Hernandez, A. The intrinsic activity of thyroxine is critical for survival and growth and regulates gene expression in neonatal liver. Thyroid 31, 528–541 (2021).
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J. & Larsen, P. R. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 23, 38–89 (2002).
Larsen, P. R., Silva, J. E. & Kaplan, M. M. Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr. Rev. 2, 87–102 (1981).
Baqui, M. M., Gereben, B., Harney, J. W., Larsen, P. R. & Bianco, A. C. Distinct subcellular localization of transiently expressed types 1 and 2 iodothyronine deiodinases as determined by immunofluorescence confocal microscopy. Endocrinology 141, 4309–4312 (2000).
Bianco, A. C. & Silva, J. E. Cold exposure rapidly induces virtual saturation of brown adipose tissue nuclear T3 receptors. Am. J. Physiol. 255, E496–E503 (1988).
Gereben, B., Goncalves, C., Harney, J. W., Larsen, P. R. & Bianco, A. C. Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol. Endocrinol. 14, 1697–1708 (2000).
Larsen, P. R. Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones. N. Engl. J. Med. 306, 23–32 (1982).
Werneck de Castro, J. P. et al. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. J. Clin. Invest. 125, 769–781 (2015).
Gereben, B., McAninch, E. A., Ribeiro, M. O. & Bianco, A. C. Scope and limitations of iodothyronine deiodinases in hypothyroidism. Nat. Rev. Endocrinol. 11, 642–652 (2015).
Ridgway, E. C. et al. Therapy of primary hypothyroidism with l-triiodothyronine: discordant cardiac and pituitary responses. Clin. Endocrinol. 13, 479–488 (1980).
Escobar-Morreale, H. F., Rey, F., Obregon, M. J. & Escobar, G. M. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology 137, 2490–2502 (1996).
Bianco, A. C. & Kim, B. S. Pathophysiological relevance of deiodinase polymorphism. Curr. Opin. Endocrinol. Diabetes Obes. 25, 341–346 (2018).
Verloop, H., Dekkers, O. M., Peeters, R. P., Schoones, J. W. & Smit, J. W. Genetics in endocrinology: genetic variation in deiodinases: a systematic review of potential clinical effects in humans. Eur. J. Endocrinol. 171, R123–R135 (2014).
Franca, M. M. et al. Human type 1 iodothyronine deiodinase (DIO1) mutations cause abnormal thyroid hormone metabolism. Thyroid 31, 202–207 (2020).
Saravanan, P. et al. Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin. Endocrinol. 57, 577–585 (2002).
Wekking, E. M. et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur. J. Endocrinol. 153, 747–753 (2005).
Marcelino, C. P. et al. Temporal pole responds to subtle changes in local thyroid hormone signaling. J. Endocr. Soc. 4, bvaa136 (2020).
Crantz, F. R., Silva, J. E. & Larsen, P. R. An analysis of the sources and quantity of 3,5,3′-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. Endocrinology 110, 367–375 (1982).
Tu, H. M. et al. Regional distribution of type 2 thyroxine deiodinase messenger ribonucleic acid in rat hypothalamus and pituitary and its regulation by thyroid hormone. Endocrinology 138, 3359–3368 (1997).
Guadano-Ferraz, A., Obregon, M. J., St Germain, D. L. & Bernal, J. The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. Proc. Natl Acad. Sci. USA 94, 10391–10396 (1997).
Freitas, B. C. et al. Paracrine signaling by glial cell-derived triiodothyronine activates neuronal gene expression in the rodent brain and human cells. J. Clin. Invest. 120, 2206–2217 (2010).
Bocco, B. M. et al. Type 2 deiodinase disruption in astrocytes results in anxiety-depressive-like behavior in male mice. Endocrinology 157, 3682–3695 (2016).
Panicker, V. et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J. Clin. Endocrinol. Metab. 94, 1623–1629 (2009).
Carle, A., Faber, J., Steffensen, R., Laurberg, P. & Nygaard, B. Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer L-T3 + L-T4 combination treatment — data using a blind, randomized, clinical study. Eur. Thyroid. J. 6, 143–151 (2017).
Panicker, V. et al. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin. Endocrinol. 71, 574–580 (2009).
Peterson, S. J. et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid 28, 707–721 (2018).
Jonklaas, J. & DeSale, S. The ages and TSH values of patients being prescribed levothyroxine. Ther. Adv. Endocrinol. Metab. 11, 2042018820937896 (2020).
Rodriguez-Gutierrez, R., Maraka, S., Ospina, N. S., Montori, V. M. & Brito, J. P. Levothyroxine overuse: time for an about face? Lancet Diabetes Endocrinol. 5, 246–248 (2017).
Watt, T. et al. Is thyroid autoimmunity per se a determinant of quality of life in patients with autoimmune hypothyroidism? Eur. Thyroid. J. 1, 186–192 (2012).
Guldvog, I. et al. Thyroidectomy versus medical management for euthyroid patients with Hashimoto disease and persisting symptoms: a randomized trial. Ann. Int. Med. 170, 453–464 (2019).
Oksnes, M. et al. Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568–576 (2012).
Jorgensen, P., Langhammer, A., Krokstad, S. & Forsmo, S. Diagnostic labelling influences self-rated health. A prospective cohort study: the HUNT Study, Norway. Fam. Pract. 32, 492–499 (2015).
Lamahewa, K., Buszewicz, M., Walters, K., Marston, L. & Nazareth, I. Persistent unexplained physical symptoms: a prospective longitudinal cohort study in UK primary care. Br. J. Gen. Pract. 69, e246–e253 (2019).
Greenhalgh, T. & Wessely, S. ‘Health for me’: a sociocultural analysis of healthism in the middle classes. Br. Med. Bull. 69, 197–213 (2004).
Centers for Disease Control and Prevention. Measuring healthy days. CDCP https://www.cdc.gov/hrqol/pdfs/mhd.pdf (2000).
Bakas, T. et al. Systematic review of health-related quality of life models. Health Qual. Life Outcomes 10, 134 (2012).
Watt, T. et al. Quality of life in patients with benign thyroid disorders. A review. Eur. J. Endocrinol. 154, 501–510 (2006).
Gao, F. et al. The Singaporean English and Chinese versions of the EQ-5D achieved measurement equivalence in cancer patients. J. Clin. Epidemiol. 62, 206–213 (2009).
Cheung, Y. B., Machin, D., Fong, K. Y., Thio, S. T. & Thumboo, J. Discriminative ability of the Short-Form 36 health survey: a tale of two versions. Qual. Life Res. 14, 555–559 (2005).
Ware, J. E. Jr, Keller, S. D., Gandek, B., Brazier, J. E. & Sullivan, M. Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment. Int. J. Technol. Assess. Health Care 11, 525–551 (1995).
Skevington, S. M. & Epton, T. How will the sustainable development goals deliver changes in well-being? A systematic review and meta-analysis to investigate whether WHOQOL-BREF scores respond to change. BMJ Glob. Health 3, e000609 (2018).
eunethta. Endpoints used for relative effectiveness assessment of pharmaceuticals: health-related quality of life and utility measures. European Network for Health Technology Assessment https://www.eunethta.eu/wp-content/uploads/2013/01/Health-related-quality-of-life.pdf (2013).
Fitzpatrick, R., Davey, C., Buxton, M. J. & Jones, D. R. Evaluating patient-based outcome measures for use in clinical trials. Health Technol. Assess. 2, 1–74 (1998).
Oczkowski, C. & O’Donnell, M. Reliability of proxy respondents for patients with stroke: a systematic review. J. Stroke Cerebrovasc. Dis. 19, 410–416 (2010).
Williams, L. S. et al. How valid are family proxy assessments of stroke patients’ health-related quality of life? Stroke 37, 2081–2085 (2006).
Guyatt, G. H., Feeny, D. H. & Patrick, D. L. Measuring health-related quality of life. Ann. Intern. Med. 118, 622–629 (1993).
Frei, A., Svarin, A., Steurer-Stey, C. & Puhan, M. A. Self-efficacy instruments for patients with chronic diseases suffer from methodological limitations — a systematic review. Health Qual. Life Outcomes 7, 86 (2009).
Jaeschke, R., Guyatt, G., Cook, D., Harper, S. & Gerstein, H. C. Spectrum of quality of life impairment in hypothyroidism. Qual. Life Res. 3, 323–327 (1994).
McMillan, C. V., Bradley, C., Woodcock, A., Razvi, S. & Weaver, J. U. Design of new questionnaires to measure quality of life and treatment satisfaction in hypothyroidism. Thyroid 14, 916–925 (2004).
Watt, T. et al. The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects. J. Clin. Endocrinol. Metab. 99, 3708–3717 (2014).
Watt, T. et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur. J. Endocrinol. 162, 161–167 (2010).
Watt, T. et al. Which domains of thyroid-related quality of life are most relevant? Patients and clinicians provide complementary perspectives. Thyroid 17, 647–654 (2007).
Watt, T. et al. Confirmatory factor analysis of the thyroid-related quality of life questionnaire ThyPRO. Health Qual. Life Outcomes 12, 126 (2014).
Watt, T. et al. Few items in the thyroid-related quality of life instrument ThyPRO exhibited differential item functioning. Qual. Life Res. 23, 327–338 (2014).
Watt, T. et al. Development of a short version of the thyroid-related patient-reported outcome ThyPRO. Thyroid 25, 1069–1079 (2015).
Watt, T. et al. Cross-cultural validity of the thyroid-specific quality-of-life patient-reported outcome measure, ThyPRO. Qual. Life Res. 24, 769–780 (2015).
Nordqvist, S. F. et al. Determining minimal important change for the thyroid-related quality of life questionnaire ThyPRO. Endocr. Connect. 10, 316–324 (2021).
Watt, T. et al. Thyroid-specific patient reported outcome (ThyPRO). ePROVIDE https://eprovide.mapi-trust.org/instruments/thyroid-specific-patient-reported-outcome#member_access_content (2021).
Canaris, G. J., Manowitz, N. R., Mayor, G. & Ridgway, E. C. The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160, 526–534 (2000).
Jaeschke, R. et al. Does treatment with l-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J. Gen. Intern. Med. 11, 744–749 (1996).
Meier, C. et al. TSH-controlled l-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J. Clin. Endocrinol. Metab. 86, 4860–4866 (2001).
Kong, W. M. et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am. J. Med. 112, 348–354 (2002).
Jorde, R. et al. Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. J. Clin. Endocrinol. Metab. 91, 145–153 (2006).
Razvi, S. et al. The beneficial effect of l-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J. Clin. Endocrinol. Metab. 92, 1715–1723 (2007).
Parle, J. et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. J. Clin. Endocrinol. Metab. 95, 3623–3632 (2010).
Reuters, V. S. et al. Effects of subclinical hypothyroidism treatment on psychiatric symptoms, muscular complaints, and quality of life. Arq. Bras. Endocrinol. Metabol. 56, 128–136 (2012).
Najafi, L. et al. Depressive symptoms in patients with subclinical hypothyroidism — the effect of treatment with levothyroxine: a double-blind randomized clinical trial. Endocr. Res. 40, 121–126 (2015).
Mooijaart, S. P. et al. Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism. J. Am. Med. Assoc. 322, 1977–1986 (2019).
Aghili, R. et al. Changes of subtests of Wechsler Memory Scale and cognitive function in subjects with subclinical hypothyroidism following treatment with levothyroxine. Arch. Med. Sci. 8, 1096–1101 (2012).
Stott, D. J., Rodondi, N., Bauer, D. C. & Group, T. S. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N. Engl. J. Med. 377, e20 (2017).
Villar, H. C., Saconato, H., Valente, O. & Atallah, A. N. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst. Rev. 2007, CD003419 (2007).
Feller, M. et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. J. Am. Med. Assoc. 320, 1349–1359 (2018).
Pearce, S. H. et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur. Thyroid. J. 2, 215–228 (2013).
Bekkering, G. E. et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. Br. Med. J. 365, l2006 (2019).
Sawka, A. M. et al. Patient context and thyrotropin levels are important when considering treatment of subclinical hypothyroidism. Thyroid 29, 1359–1363 (2019).
Winther, K. H. et al. Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. PLoS ONE 11, e0156925 (2016).
Roos, A., Linn-Rasker, S. P., van Domburg, R. T., Tijssen, J. P. & Berghout, A. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. Arch. Intern. Med. 165, 1714–1720 (2005).
Schroeder, P. R. et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 91, 878–884 (2006).
Lee, J. et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 20, 173–179 (2010).
Taieb, D. et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin. Endocrinol. 71, 115–123 (2009).
Chow, S. M. et al. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning. Laryngoscope 116, 2060–2066 (2006).
Quinque, E. M., Villringer, A., Kratzsch, J. & Karger, S. Patient-reported outcomes in adequately treated hypothyroidism — insights from the German versions of ThyDQoL, ThySRQ and ThyTSQ. Health Qual. Life Outcomes 11, 68 (2013).
Kelderman-Bolk, N., Visser, T. J., Tijssen, J. P. & Berghout, A. Quality of life in patients with primary hypothyroidism related to BMI. Eur. J. Endocrinol. 173, 507–515 (2015).
Walsh, J. P. et al. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J. Clin. Endocrinol. Metab. 91, 2624–2630 (2006).
Samuels, M. H., Kolobova, I., Niederhausen, M., Janowsky, J. S. & Schuff, K. G. Effects of altering levothyroxine (l-T4) doses on quality of life, mood, and cognition in l-T4 treated subjects. J. Clin. Endocrinol. Metab. 103, 1997–2008 (2018).
dos Santos Vigário, P. et al. Inadequate levothyroxine replacement for primary hypothyroidism is associated with poor health-related quality of life — a Brazilian multicentre study. Endocrine 44, 434–440 (2013).
Klaver, E. I. et al. Thyroid hormone status and health-related quality of life in the LifeLines Cohort Study. Thyroid 23, 1066–1073 (2013).
Guglielmi, R. et al. Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocr. Metab. Immune Disord. Drug. Targets 18, 235–240 (2018).
Jonklaas, J. et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement. Thyroid 24, 1670–1751 (2014).
Kaminski, J., Miasaki, F. Y., Paz-Filho, G., Graf, H. & Carvalho, G. A. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. Arch. Endocrinol. Metab. 60, 562–572 (2016).
Shakir, M. K. M. et al. Comparative effectiveness of levothyroxine, desiccated thyroid extract, and levothyroxine+liothyronine in hypothyroidism. J. Clin. Endocrinol. Metab. 106, e4400–e4413 (2021).
Nygaard, B., Jensen, E. W., Kvetny, J., Jarlov, A. & Faber, J. Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur. J. Endocrinol. 161, 895–902 (2009).
Bunevicius, R., Kazanavicius, G., Zalinkevicius, R. & Prange, A. J. Jr Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N. Engl. J. Med. 340, 424–429 (1999).
Valizadeh, M. et al. Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. Endocr. Res. 34, 80–89 (2009).
Saravanan, P., Simmons, D. J., Greenwood, R., Peters, T. J. & Dayan, C. M. Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. J. Clin. Endocrinol. Metab. 90, 805–812 (2005).
Walsh, J. P. et al. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J. Clin. Endocrinol. Metab. 88, 4543–4550 (2003).
Jonklaas, J. et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid 31, 156–182 (2021).
Jonklaas, J. et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Eur. Thyroid. J. 10, 10–38 (2021).
Dumitrescu, A. M. et al. Extended absorption of liothyronine from poly-zinc-liothyronine (PZL): results from a phase 1, double-blind, randomized, and controlled study in humans. Thyroid https://doi.org/10.1089/thy.2021.0304 (2021).
Pepper, G. M. & Casanova-Romero, P. Y. Letter to the Editor. Endocr. Pract. 24, 230 (2018).
Hoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W. & Shakir, M. K. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J. Clin. Endocrinol. Metab. 98, 1982–1990 (2013).
Bunevicius, R. & Prange, A. J. Jr. Psychiatric manifestations of Graves’ hyperthyroidism: pathophysiology and treatment options. CNS Drugs 20, 897–909 (2006).
Kelly, T. An examination of myth: a favorable cardiovascular risk–benefit analysis of high-dose thyroid for affective disorders. J. Affect. Disord. 177, 49–58 (2015).
Lewis, D. H., Kumar, J., Goulden, P. & Barnes, D. J. Improvements in quality of life in hypothyroid patients taking Armour thyroid. Endocr. Abstr. 15, P359 (2008).
Weetman, A. P. An update on the pathogenesis of Hashimoto’s thyroiditis. J. Endocrinol. Invest. 44, 883–890 (2021).
Posabella, A. et al. Derivation of thyroid follicular cells from pluripotent stem cells: insights from development and implications for regenerative medicine. Front. Endocrinol. 12, 666565 (2021).
Bullmore, E. The art of medicine: inflamed depression. Lancet 392, 1189–1190 (2018).
Thvilum, M. et al. Type and extent of somatic morbidity before and after the diagnosis of hypothyroidism. a nationwide register study. PLoS ONE 8, e75789 (2013).
Thvilum, M. et al. Increased psychiatric morbidity before and after the diagnosis of hypothyroidism: a nationwide register study. Thyroid 24, 802–808 (2014).
Thvilum, M., Brandt, F., Brix, T. H. & Hegedus, L. Hypothyroidism is a predictor of disability pension and loss of labor market income: a Danish register-based study. J. Clin. Endocrinol. Metab. 99, 3129–3135 (2014).
Heiberg Brix, T., Ferlov-Schwensen, C., Thvilum, M. & Hegedüs, L. Death by unnatural causes, mainly suicide, is increased in patients with Hashimoto’s thyroiditis. A nationwide Danish register study. Endocrine 65, 616–622 (2019).
Brix, T. H. & Hegedus, L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin. Endocrinol. 76, 457–464 (2012).
Perros, P. et al. The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: a narrative review. Clin. Endocrinol. https://doi.org/10.1111/cen.14473 (2021).
Nagy, E. V., Perros, P., Papini, E., Katko, M. & Hegedus, L. New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat? Thyroid 31, 193–201 (2021).
Michaelsson, L. F. et al. Levothyroxine/Liothyronine combination therapy and quality of life: is it all about weight loss? Eur. Thyroid. J. 7, 243–250 (2018).
Fadeyev, V. V., Morgunova, T. B., Melnichenko, G. A. & Dedov, I. I. Combined therapy with l-thyroxine and l-triiodothyronine compared to l-thyroxine alone in the treatment of primary hypothyroidism. Hormones 9, 245–252 (2010).
Acknowledgements
J.J. has received support from NIDCR grant R01DE025822 and NCATS grant UL1TR001409. A.C.B. has received support from NIH grants DK58538 and DK65055.
Author information
Authors and Affiliations
Contributions
L.H., A.C.B., J.J., S.H.P., A.P.W. and P.P. researched data for the article, wrote the article, contributed substantially to the discussion of content and reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
S.H.P. has received speaker fees from Quidel, Sanofi and Berlin Chemie, and consulting fees from Apitope. P.P. has received consulting fees from IBSA Institut Biochimique and speaker fees from Berlin Chemie. L.H. has received consulting fees from IBSA Institut Biochimique and speaker fees from Berlin Chemie. A.C.B. is a consultant for AbbVie, Allergan, Synthonics, Sention, and Thyron. J.J. and A.P.W. declare no competing interests.
Additional information
Peer review information
Nature Reviews Endocrinology thanks B. Biondi and the other, anonymous, peer reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Free T4
-
T4 that is not bound to protein in the circulation and is therefore available to act on tissues
- Acrophase
-
The time at which a peak in a circadian rhythm occurs
- Thyrotrophs
-
Cells in the anterior pituitary gland that secrete TSH
- Tanycytes
-
Specialized ependymal cells lining the walls of the third ventricle
- Responsive
-
The responsiveness of an instrument determines its ability to detect relevant clinical changes over time
- Acceptable
-
How acceptable an instrument is determines its ease of use by participants
- Test–retest reliability
-
Stability of the scores obtained from the same person on two or more separate occasions
- Minimal important change
-
The smallest change in an outcome that is perceived by an individual patient as important
- Thyrotoxic
-
A metabolic state characterized by elevated serum levels of tri-iodothyronine
- Content validity
-
Extent to which the items tested are representative of the entire domain the test seeks to measure
Rights and permissions
About this article
Cite this article
Hegedüs, L., Bianco, A.C., Jonklaas, J. et al. Primary hypothyroidism and quality of life. Nat Rev Endocrinol 18, 230–242 (2022). https://doi.org/10.1038/s41574-021-00625-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-021-00625-8
This article is cited by
-
Terapia dell’ipotiroidismo primitivo: un ormone o due ormoni?
L'Endocrinologo (2024)
-
Severity of hypothyroidism is inversely associated with impaired quality of life in patients referred to an endocrine clinic
Thyroid Research (2023)
-
Use of thyroid hormones in hypothyroid and euthyroid patients: a 2022 THESIS questionnaire survey of members of the Latin American Thyroid Society (LATS)
Thyroid Research (2023)
-
Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A THESIS questionnaire survey of members of the Irish Endocrine Society
Irish Journal of Medical Science (1971 -) (2023)
-
Primary human thyrocytes maintained the function of thyroid hormone production and secretion in vitro
Journal of Endocrinological Investigation (2023)